IDENTIFICATION OF INFLIXIMAB TARGET EXPOSURE IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: PHARMACOKINETIC/PHARMACODYNAMIC ASSESSMENT OF CLINICAL DATA.

Xiong Y.; Bauman L.; Mizuno T.; Fukuda T.; Minar P.; Rosen M.; Vinks A. A.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >IDENTIFICATION OF INFLIXIMAB TARGET EXPOSURE IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: PHARMACOKINETIC/PHARMACODYNAMIC ASSESSMENT OF CLINICAL DATA.

【24h】

IDENTIFICATION OF INFLIXIMAB TARGET EXPOSURE IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: PHARMACOKINETIC/PHARMACODYNAMIC ASSESSMENT OF CLINICAL DATA.

机译：克罗恩疾病儿科患者英夫利昔单抗靶向鉴定：临床资料的药代动力学/药效学评估。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2019年第1期|共2页
作者
Xiong Y.; Bauman L.; Mizuno T.; Fukuda T.; Minar P.; Rosen M.; Vinks A. A.;
展开▼
作者单位

Cincinnati Childrens Hosp Med Ctr Div Clin Pharmacol Cincinnati OH 45229 USA;

Univ Calif San Diego Dept Pediat La Jolla CA 92093 USA;

Cincinnati Childrens Hosp Med Ctr Div Clin Pharmacol Cincinnati OH 45229 USA;

Cincinnati Childrens Hosp Med Ctr Div Clin Pharmacol Cincinnati OH 45229 USA;

Univ Cincinnati Coll Med Dept Pediat Cincinnati OH USA;

Univ Cincinnati Coll Med Dept Pediat Cincinnati OH USA;

Cincinnati Childrens Hosp Med Ctr Div Clin Pharmacol Cincinnati OH 45229 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. IDENTIFICATION OF INFLIXIMAB TARGET EXPOSURE IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: PHARMACOKINETIC/PHARMACODYNAMIC ASSESSMENT OF CLINICAL DATA. [J] . Xiong Y., Bauman L., Mizuno T., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：克罗恩疾病儿科患者英夫利昔单抗靶向鉴定：临床资料的药代动力学/药效学评估。
2. Letter to Dreesen et al. on their article "Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease"-A comprehensive review of infliximab population pharmacokinetic modelling publications [J] . Le Tilly Olivier, Bejan-Angoulvant Theodora, Paintaud Gilles, British Journal of Clinical Pharmacology . 2021,第3期

机译：德莱森等人。关于他们的文章“毛细血管暴露，粪便抗癌素，患者患者内镜缓解患者的关系的建模” - 富胎巴比人群药代动力学造型出版物的全面综述
3. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease [J] . Ternant David, Berkane Zahir, Picon Laurence, Clinical pharmacokinetics . 2015,第5期

机译：炎症和FCGR3A基因型对克罗恩病患者英夫利昔单抗药代动力学和复发时间的影响评估
4. Understanding Crohn's disease patients reaction to infliximab from facebook: A medical perspective [C] . M. Roccetti, P. Salomoni, C. Prandi, Proceedings of the 2016 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining . 2016

机译：从facebook了解克罗恩病患者对英夫利昔单抗的反应：医学观点
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Case Report: Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature [O] . Farhan Mohammad, Abhirami Vivekanandarajah, Housam Haddad, 1929

机译：病例报告：克罗恩病并暴露于英夫利昔单抗的患者的急性早幼粒细胞白血病（APL）：罕见的临床表现和文献复习
7. DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX [O] . E Dreesen, G DHaens, F Baert, 2018

机译：DOP047英夫利昔单抗曝光预测有源克罗恩病患者的优异内窥镜结果：定制的药代动力学 - 药物动力学分析

IDENTIFICATION OF INFLIXIMAB TARGET EXPOSURE IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE: PHARMACOKINETIC/PHARMACODYNAMIC ASSESSMENT OF CLINICAL DATA.

著录项

相似文献

相关主题

期刊订阅